Communiqués Autolus Therapeutics plc

Actions

AUTL

US05280R1005

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
1,940 ^USD	+4,30 %		-4,43 %	-2,51 %

30/09	Les actions européennes cotées aux États-Unis sous forme de certificats américains de dépôt reculent mercredi	MT
28/09	Les actions européennes cotées aux États-Unis sous forme de certificats américains de dépôt commencent la semaine en légère baisse lundi	MT

Communiqués

09/09	Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis	GL
09/09	Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis	AQ
11/08	Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates	GL
11/08	Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates	AQ
03/08	Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026	GL
03/08	Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors	GL
01/07	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
25/06	Autolus Therapeutics to Participate in Upcoming Investor Conference	GL
12/06	Autolus Therapeutics Receives Prix Galien UK Award	GL
27/05	Autolus Therapeutics to Participate in Upcoming Investor Conferences	GL
21/05	Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026	GL
14/05	Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates	GL
14/05	Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates	AQ
05/05	Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026	GL
29/04	Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction	GL
21/04	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
13/04	Autolus Therapeutics : Presentation - (260409 autl corporate presentation april 2026)	PU
07/04	Autolus Therapeutics to Participate in Upcoming Investor Conferences	GL
27/03	Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates	GL
16/03	Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026	GL
24/02	Autolus Therapeutics to Participate in Upcoming Investor Conferences	GL
04/02	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
12/01	Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026	GL
06/01	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform	BU
06/01	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform	GL